Will Beta

Main Menu

  • Volatility
  • Systematic Risk
  • Returns Of Assets
  • Beta Data
  • Finance Debt

Will Beta

Header Banner

Will Beta

  • Volatility
  • Systematic Risk
  • Returns Of Assets
  • Beta Data
  • Finance Debt
Beta Data
Home›Beta Data›Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PT lowered to €57.00 at Societe Generale

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PT lowered to €57.00 at Societe Generale

By Rogers Jennifer
February 27, 2022
0
0

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) saw its target price lowered by Societe Generale investment analysts from €61.00 ($69.32) to €57.00 ($64.77) in a research report delivered to clients and investors on Friday, Fly reports.

Other research analysts have also recently published research reports on the company. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to an “underperform” rating and lowered its price target for the company from $32.40 to $30.30 in a report from the Friday February 11. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a Tuesday, Nov. 9 research note. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Fresenius Medical Care AG & Co. KGaA in a Wednesday, Dec. 1 research note. HSBC began covering Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday November 23. They issued a “hold” rating on the stock. Finally, Royal Bank of Canada lowered its price target on Fresenius Medical Care AG & Co. KGaA from $42.00 to $35.00 and set a “sector performance” rating on the stock in a memo. research from Wednesday, November 17. Two equity research analysts gave the stock a sell rating, eight gave the stock a hold rating and four gave the stock a buy rating. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Hold” and an average target price of $39.46.

(A d)

It’s scientific breakthroughs like this that give investors like you the chance to get in early on the companies that will revolutionize the world…

And you might only get once in a lifetime opportunity to invest in something that big…

Shares of Share Fresenius Medical Care AG & Co. KGaA traded at $0.91 on Friday, reaching $32.70. 440,004 shares of the company were traded, with an average volume of 468,015. The stock has a fifty-day moving average price of $33.05 and a 200-day moving average price of $34.38. The company has a market cap of $19.16 billion, a price-to-earnings ratio of 17.49, a growth price-to-earnings ratio of 15.72, and a beta of 1.19. The company has a current ratio of 1.07, a quick ratio of 0.78 and a debt ratio of 0.49. Fresenius Medical Care AG & Co. KGaA has a fifty-two week minimum of $29.71 and a fifty-two week maximum of $42.45.

Several institutional investors and hedge funds have recently increased or reduced their stake in FMS. FMR LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 40.5% during the 2nd quarter. FMR LLC now owns 29,152 shares of the company worth $1,212,000 after purchasing an additional 8,397 shares in the last quarter. Pzena Investment Management LLC acquired a new equity position in Fresenius Medical Care AG & Co. KGaA during Q3 for a value of approximately $224,080,000. Nuveen Asset Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 3.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 520,440 shares of the company worth $21,635,000 after purchasing an additional 17,777 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 200.1% during the second quarter. JPMorgan Chase & Co. now owns 6,488 shares of the company worth $270,000 after buying 4,326 more shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new equity position in Fresenius Medical Care AG & Co. KGaA during Q3 for a value of approximately $6,977,000. Institutional investors hold 4.89% of the company’s shares.

About Fresenius Medical Care AG & Co. KGaA (Get a rating)

Fresenius Medical Care AG & Co KGaA is committed to providing products and services to patients with chronic kidney disease. It also develops and manufactures a variety of healthcare products, including dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Read more

The Fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Related posts:

  1. Morgan Stanley lowers its price target (NASDAQ: INCY) to $ 85.00
  2. Red Light Holland iMicro Digital Care app and teleconsultation launched
  3. CME says over 100,000 micro-bitcoin futures traded in the first six days
  4. Euro-dollar draws confidence from ZEW data and USD Ebbing
Tagsasset managementwall street

Recent Posts

  • Racing Louisville uses transfer window to build asset base
  • Global Beta-Eudesmol Market 2022 to 2028 Growth Prospects and Key Industry Players Santa Cruz Biotechnology (SCBT), Merck KGaA (Sigma-Aldrich), AdooQ – Instant Interview
  • Saris Cycling Group, victim of the “Covid whiplash”, restructures to be sold
  • Fatigue Impacts Sexual Problems in Chinese Women With Systemic Lupus Erythematosus | BMC Women’s Health
  • Investor opinion: “Baillie Gifford taught me…

Archives

  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021

Categories

  • Beta Data
  • Finance Debt
  • Returns Of Assets
  • Systematic Risk
  • Volatility
  • Terms and Conditions
  • Privacy Policy